Assay Development Disease Drug Development 
Conversations in Drug Development Trends
JANUARY 6, 2025
Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis Revolutionizing Therapeutic Development with Cutting-Edge Bioanalysis Automation Cutting-edge advancements in bioanalysis (BioA) and drug R&D are reshaping the future of preventative and interventional care, but how do we harness these to their fullest potential?
Drug Target Review
APRIL 7, 2025
The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions. References Sun D, et al. doi:10.1016/j.apsb.2022.02.002.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development.
Elrig
APRIL 29, 2024
My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK.
Agency IQ
FEBRUARY 2, 2024
The revisions flesh out considerations for use of biomarkers at all stages of product development and add new content on rare cancers and platform trial designs. after ischemic heart disease and stroke. The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. were from cancer.
Expert insights. Personalized for you.
52 
Let's personalize your content